Company Analysis Supernus Pharmaceuticals, Inc.
1. Summary
Advantages
- The stock's return over the last year (25.36%) is higher than the sector average (-15.96%).
- Current debt level 2.95% is below 100% and has decreased over 5 years from 29.75%.
Disadvantages
- Price (29.68 $) is higher than fair price (0.1117 $)
- Dividends (0%) are below the sector average (0.5442%).
- The company's current efficiency (ROE=0.1428%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Supernus Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 2.4% | -16.8% | 0.9% |
| 90 days | 18% | -20.8% | 6.4% |
| 1 year | 25.4% | -16% | 32.2% |
SUPN vs Sector: Supernus Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 41.32% over the past year.
SUPN vs Market: Supernus Pharmaceuticals, Inc. has significantly underperformed the market by -6.79% over the past year.
Stable price: SUPN is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: SUPN with weekly volatility of 0.4877% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (29.68 $) is higher than the fair price (0.1117 $).
Price is higher than fair: The current price (29.68 $) is 99.6% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (1232.88) is higher than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (1232.88) is higher than that of the market as a whole (48.79).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.76) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (1.76) is lower than that of the market as a whole (3.36).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.67) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (2.67) is lower than that of the market as a whole (10.23).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (16.17) is higher than that of the sector as a whole (-22.15).
EV/Ebitda vs Market: The company's EV/Ebitda (16.17) is lower than that of the market as a whole (28.28).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -19.79% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-19.79%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (123.79%).
5.4. ROE
ROE vs Sector: The company's ROE (0.1428%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (0.1428%) is lower than that of the market as a whole (10.82%).
5.5. ROA
ROA vs Sector: The company's ROA (0.0934%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (0.0934%) is lower than that of the market as a whole (6.51%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (5.83%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (5.83%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5442%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 27.12.2024 | Khattar Jack A. President, CEO |
Purchase | 37.06 | 1 951 100 | 52 640 |
| 27.12.2024 | Rubin Jonathan SVP, Chief Medical Officer |
Purchase | 36.91 | 96 889 | 2 625 |
| 30.07.2024 | TAMI TILLOTSON MARTIN Former Officer |
Purchase | 30.56 | 88 624 | 2 900 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
